Accelerate Diagnostics Dirección

Dirección controles de criterios 1/4

El CEO de Accelerate Diagnostics' es Jack Phillips , nombrado en Feb 2020, tiene una permanencia de 4.17 años. compensación anual total es $3.00M, compuesta por 19.8% salario y 80.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.75% de las acciones de la empresa, por valor de $139.95K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 4.2 años, respectivamente.

Información clave

Jack Phillips

Chief Executive Officer (CEO)

US$3.0m

Compensación total

Porcentaje del salario del CEO	19.8%
Permanencia del CEO	4.3yrs
Participación del CEO	0.8%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jack Phillips en comparación con los beneficios de Accelerate Diagnostics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$3m	US$595k	-US$62m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$80m
Mar 31 2023	n/a	n/a	-US$66m
Dec 31 2022	US$2m	US$595k	-US$62m
Sep 30 2022	n/a	n/a	-US$71m
Jun 30 2022	n/a	n/a	-US$64m
Mar 31 2022	n/a	n/a	-US$67m
Dec 31 2021	US$3m	US$595k	-US$78m
Sep 30 2021	n/a	n/a	-US$74m
Jun 30 2021	n/a	n/a	-US$84m
Mar 31 2021	n/a	n/a	-US$81m
Dec 31 2020	US$4m	US$555k	-US$78m
Sep 30 2020	n/a	n/a	-US$81m
Jun 30 2020	n/a	n/a	-US$82m
Mar 31 2020	n/a	n/a	-US$84m
Dec 31 2019	US$12m	US$162k	-US$84m

Compensación vs. Mercado: La compensación total de Jack($USD3.00M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD345.35K).

Compensación vs. Ingresos: La compensación de Jack ha aumentado mientras la empresa no es rentable.

CEO

Jack Phillips (57 yo)

4.3yrs

Permanencia

US$3,004,105

Compensación

Mr. Jack Phillips has been Chief Executive Officer, President and Director of Accelerate Diagnostics, Inc. since February 1, 2020. Mr. Phillips served as Chief Operating Officer of Accelerate Diagnostics,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jack Phillips	CEO, President & Director	4.3yrs	US$3.00m	0.75% $ 143.6k
David Patience	Chief Financial Officer	1.1yrs	US$1.16m	0.24% $ 45.1k
Lawrence Mertz	Chief Technology Officer	1.9yrs	US$952.16k	0.37% $ 71.5k
Maya Gowri	Senior VP & Head of Operations	1.3yrs	sin datos	sin datos
Laura Pierson	Investor Relations Officer	no data	sin datos	sin datos
John Meduri	Chief Strategy Officer	8.2yrs	sin datos	sin datos
Chris Thode	Senior Vice President of US Commercial	1.3yrs	sin datos	sin datos
Rita Boukamel	Senior VP & Head of EMEA	1.2yrs	sin datos	sin datos

1.3yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0H8E no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jack Phillips	CEO, President & Director	4.3yrs	US$3.00m	0.75% $ 143.6k
John Patience	Independent Director	11.9yrs	US$231.32k	3.1% $ 591.7k
Jack Schuler	Independent Director	11.9yrs	US$231.32k	32.14% $ 6.1m
Hany Massarany	Independent Chairman of the Board	4yrs	US$231.32k	0.13% $ 24.0k
Louise Francesconi	Independent Director	4.4yrs	US$231.32k	0.097% $ 18.4k
Marran J. Ogilvie	Independent Director	less than a year	US$233.68k	sin datos
Matthew Strobeck	Independent Director	11.8yrs	US$231.32k	0.94% $ 180.3k
Marin Kollef	Scientific Advisory Board Member	no data	sin datos	sin datos
Connie Price	Scientific Advisory Board Member	no data	sin datos	sin datos
Richard Wunderink	Scientific Advisory Board Member	no data	sin datos	sin datos
Wayne Burris	Independent Director	2.3yrs	US$231.32k	0.0039% $ 739.1
Jenny Regan	Independent Director	less than a year	US$233.68k	sin datos

4.3yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de 0H8E se considera experimentada (4.2 años de antigüedad promedio).

Accelerate Diagnostics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024

Insufficient new directors

Accelerate Diagnostics, Inc. Announces Resignation of Ron Price as Chief Commercial Officer

Insider recently bought US$80k worth of stock

Accelerate Diagnostics, Inc., Annual General Meeting, May 12, 2022

Accelerate Diagnostics, Inc. Elects Wayne C. Burris as Member of the Board

Recent updates

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of Nasdaq

Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC

Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living Trust

Accelerate Diagnostics, Inc. has completed a Composite Units Offering.

Accelerate Diagnostics, Inc. has completed a Composite Units Offering.

Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital Market

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.15 loss in 3Q 2021)

Insufficient new directors

Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Accelerate Diagnostics Submits 510(K) Application to FDA for Gram-Negative Menu Expansion and Breakpoint Updates for the Accelerate Phenotest(R) BC Kit

Accelerate Diagnostics, Inc. Announces Resignation of Ron Price as Chief Commercial Officer

Accelerate Diagnostics, Inc. Provides Earnings Guidance for the Year 2022

Insider recently bought US$80k worth of stock

Accelerate Diagnostics, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.35 loss in 2Q 2021)

Accelerate Diagnostics Announces Commercialization of its Accelerate Arc System Having Completed IVD Registration with FDA

First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.41 loss in 1Q 2021)

Accelerate Diagnostics, Inc., Annual General Meeting, May 12, 2022

Accelerate Diagnostics, Inc. Announces Launch of Accelerate Arc™ Module and BC Kit

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Accelerate Diagnostics, Inc. Elects Wayne C. Burris as Member of the Board

Insider recently bought US$66k worth of stock

Independent Director recently bought US$524k worth of stock

Independent Director recently bought US$196k worth of stock

Accelerate Diagnostics, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Independent Director recently bought US$277k worth of stock

Independent Director recently bought US$369k worth of stock

Independent Director recently bought US$606k worth of stock

Accelerate Diagnostics, Inc. Announces New Accelerate Pheno System Multi-Center Study Published in Clinical Infectious Diseases

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020)

Accelerate Diagnostics, Inc. announced that it has received $1.55 million in funding

Independent Director recently bought US$1.0m worth of stock

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.35 loss in 2Q 2020)

Accelerate Diagnostics, Inc. to present New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits at ECCMID 2021

First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.39 loss in 1Q 2020)

Accelerate Diagnostics, Inc. Announces Roland D. Diggelmann Decision Not to Stand for Re-Election to Its Board

Full year 2020 earnings released: US$1.40 loss per share (vs US$1.55 loss in FY 2019)

Revenue misses expectations

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad